Olaparib plus Abiraterone

[snoraste]

Phase II study shows some benefit of combination therapy for mCRPC in patients with HRR. But not seeing anything on early administration of the combined therapy prior to being casteration resistant.

practiceupdate.com/C/69314/...

[AlanMeyer]

That struck me as a strange study report. The authors state:

"Patients with metastatic castration-resistant prostate cancer and homologous recombination repair (HRR) mutations have a better response to treatment with the poly(ADP-ribose) polymerase inhibitor olaparib than patients without HRR mutations. Preclinical data suggest synergy between olaparib and androgen pathway inhibitors. We aimed to assess the efficacy of olaparib plus the androgen pathway inhibitor abiraterone in patients with metastatic castration-resistant prostate cancer regardless of HRR mutation status."

What seems strange to me is that they don't report how many men in the study had the HRR mutations and how many didn't, or what the progression free survival was for men who had the mutations and men that didn't. We don't even know from the report whether the men were tested for HRR mutations. Maybe 90% of the men had the mutations. Maybe only 10% had them. Maybe none had them. Wouldn't that be important to know in evaluating the results?

I don't think that the failure to report this information makes the study worthless, but it does seem like it could be worth more if the information were included.

Alan

[snoraste in reply to AlanMeyer]

I agree. The study lacks details as published here.